利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Non-natural galanin receptor ligands
    1.
    发明授权
    Non-natural galanin receptor ligands 失效
    非天然甘丙肽受体配体

    公开(公告)号：US06747060B2

    公开(公告)日：2004-06-08

    申请号：US10155376

    申请日：2002-05-24

    申请人： Kulliki Saar ,  Tamas Bartfai ,  Ulo Langel ,  Gerd Hallnemo ,  Sven Hellberg

    发明人： Kulliki Saar ,  Tamas Bartfai ,  Ulo Langel ,  Gerd Hallnemo ,  Sven Hellberg

    IPC分类号： A61K3135

    CPC分类号： C07K5/06078 ,  A61K38/00

    摘要： Compounds which are non-natural galanin receptor ligands are disclosed. The ligands are of small size, have agonist or antagonist galanin activity and may cross the blood-brain barrier to displace galanin from galanin receptors. The ligands are useful as medicaments for treatment of convulsions (e.g. in epilepsy), diseases and disorders related to endocrinology (e.g., growth hormone, insulin or prolactin release), tumors expressing galanin receptors, feeding disorders pain, allodynia, psychiatric disorders such as depression (involving e.g., noradrenaline or serotonin), cognitive disorders (e.g. Alzeimer's disease), and the like.

    摘要翻译： 公开了非天然甘氨酸受体配体的化合物。 配体具有小尺寸，具有激动剂或拮抗剂甘丙肽活性，并且可以穿过血脑屏障以从甘丙肽受体取代甘丙肽。 配体可用作治疗惊厥（例如癫痫），与内分泌学（例如生长激素，胰岛素或催乳素释放）相关的疾病和病症的药物，表达甘丙肽受体的肿瘤，进食障碍性疼痛，异常性疼痛，抑郁症等精神疾病 （例如，去甲肾上腺素或5-羟色胺），认知障碍（例如Alzeimer病）等。

    METHOD AND COMPOSITION FOR CREATING CONDITIONAL LETHALITY FOR VIRUS MUTANTS AND FOR ELIMINATING THE VIABILITY OF AN EUKARYOTIC CELL
    6.
    发明申请
    METHOD AND COMPOSITION FOR CREATING CONDITIONAL LETHALITY FOR VIRUS MUTANTS AND FOR ELIMINATING THE VIABILITY OF AN EUKARYOTIC CELL 审中-公开
    用于为病毒突变体创造条件性遗传和消除真核细胞的可能性的方法和组合物

    公开(公告)号：US20120282225A1

    公开(公告)日：2012-11-08

    申请号：US13500010

    申请日：2010-09-13

    申请人： Samir El-Andaloussi ,  Gregory Heller ,  Ulo Langel ,  Taavi Lehto ,  Andres Merits ,  Liane Ulper

    发明人： Samir El-Andaloussi ,  Gregory Heller ,  Ulo Langel ,  Taavi Lehto ,  Andres Merits ,  Liane Ulper

    IPC分类号： A61K35/76 ,  A61P35/00 ,  C12N15/113

    CPC分类号： A61K35/761 ,  A61K35/768 ,  C12N7/00 ,  C12N15/11 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/11 ,  C12N2320/33 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2710/10361 ,  C12N2770/36132 ,  C12N2770/36143 ,  C12N2770/36161 ,  C12N2840/44

    摘要： Viral vectors are potential tools for eliminating the viability of eukaryotic cells in anti-cancer therapies since they can efficiently destroy the cancer cells and trigger an immune response against tumours. Typically viruses are not specific to cancer cells and all methods known in art aiming to the construction of cancer-specific viruses suffer from serious problems. The present invention presents a universal method to overcome these problems and is usable for any DNA virus replicating in nucleus or for any layered vector of RNA viruses. In this method the viral gene expression and/or replication will be blocked by the introduction of one or more aberrantly spliced introns into crucial gene expression units of the virus or vector. Lethal effect of these mutations is reverted in a controlled manner by the delivery of splice-switch oligonucleotide (s) correcting the introduced defects and restoring the biological functionality of the virus or vector, including cytolytic properties.

    摘要翻译： 病毒载体是消除抗癌治疗中真核细胞活力的潜在工具，因为它们可以有效地破坏癌细胞并引发针对肿瘤的免疫应答。 通常，病毒对癌细胞不是特异性的，并且用于构建癌症特异性病毒的艺术中已知的所有方法都遭受严重问题。 本发明提出了克服这些问题的通用方法，并且可用于在核中或任何分层RNA病毒载体中复制的任何DNA病毒。 在该方法中，通过将一个或多个异常剪接的内含子引入病毒或载体的关键基因表达单元中，病毒基因表达和/或复制将被阻断。 通过递送剪接切换寡核苷酸来校正引入的缺陷并恢复病毒或载体的生物学功能，包括细胞溶解性质，这些突变的致死作用以受控的方式被还原。